129 related articles for article (PubMed ID: 21196293)
1. Aberrant methylation as a main mechanism of TSGs silencing in PTC.
Czarnecka K; Pastuszak-Lewandoska D; Migdalska-Sek M; Nawrot E; Brzezinski J; Dedecjus M; Pomorski L; Brzezianska E
Front Biosci (Elite Ed); 2011 Jan; 3(1):137-57. PubMed ID: 21196293
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma.
Huang Y; de la Chapelle A; Pellegata NS
Int J Cancer; 2003 May; 104(6):735-44. PubMed ID: 12640681
[TBL] [Abstract][Full Text] [Related]
3. Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis.
Weber F; Aldred MA; Morrison CD; Plass C; Frilling A; Broelsch CE; Waite KA; Eng C
J Clin Endocrinol Metab; 2005 Feb; 90(2):1149-55. PubMed ID: 15546898
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Significance of Overall Frequency of Allelic Loss (OFAL) in Lesions Derived from Thyroid Follicular Cell.
Migdalska-Sęk M; Czarnecka KH; Kusiński M; Pastuszak-Lewandoska D; Nawrot E; Kuzdak K; Brzeziańska-Lasota E
Mol Diagn Ther; 2019 Jun; 23(3):369-382. PubMed ID: 30747408
[TBL] [Abstract][Full Text] [Related]
5. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
[TBL] [Abstract][Full Text] [Related]
6. Screening of selected genomic areas potentially involved in thyroid neoplasms.
Oriola J; Halperin I; Mallofré C; Muntané J; Angel M; Rivera-Fillat F
Eur J Cancer; 2001 Dec; 37(18):2470-4. PubMed ID: 11720845
[TBL] [Abstract][Full Text] [Related]
7. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.
Yin DT; Wu W; Li M; Wang QE; Li H; Wang Y; Tang Y; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):507-14. PubMed ID: 23702469
[TBL] [Abstract][Full Text] [Related]
8. Methylation of tumour suppressor genes associated with thyroid cancer.
Botezatu A; Iancu IV; Plesa A; Manda D; Popa O; Bostan M; Mihaila M; Albulescu A; Fudulu A; Vladoiu SV; Huica I; Dobrescu R; Anton G; Badiu C
Cancer Biomark; 2019; 25(1):53-65. PubMed ID: 31006665
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
10. Silencing of the maspin gene by promoter hypermethylation in thyroid cancer.
Boltze C; Schneider-Stock R; Quednow C; Hinze R; Mawrin C; Hribaschek A; Roessner A; Hoang-Vu C
Int J Mol Med; 2003 Oct; 12(4):479-84. PubMed ID: 12964023
[TBL] [Abstract][Full Text] [Related]
11. High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor gene.
Farrand K; Delahunt B; Wang XL; McIver B; Hay ID; Goellner JR; Eberhardt NL; Grebe SK
J Clin Endocrinol Metab; 2002 Oct; 87(10):4715-21. PubMed ID: 12364463
[TBL] [Abstract][Full Text] [Related]
12. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
13. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.
Hogg RP; Honorio S; Martinez A; Agathanggelou A; Dallol A; Fullwood P; Weichselbaum R; Kuo MJ; Maher ER; Latif F
Eur J Cancer; 2002 Aug; 38(12):1585-92. PubMed ID: 12142046
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of the RSK4 promoter associated with BRAF V600E promotes papillary thyroid carcinoma.
Yin Y; Che K; Hu J; Hua H; Dong A; Wang J; Yu J; Zhang Q; Zhao S; Zhao Y; Wang P; Wang F; Wang Y; Chi J; Sun W
Int J Oncol; 2020 May; 56(5):1284-1293. PubMed ID: 32319586
[TBL] [Abstract][Full Text] [Related]
16. [Investigations to the influence of tumor supressor gene p16 inactivation on the prognosis of head and neck squamous cell carcinoma].
Koscielny S; V Eggeling F; Dahse R
Laryngorhinootologie; 2004 Jun; 83(6):374-80. PubMed ID: 15197677
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability in thyroid papillary carcinoma and multinodular hyperplasia.
Dobosz T; Lukienczuk T; Sasiadek M; Kuczyńska A; Jankowska E; Blin N
Oncology; 2000 May; 58(4):305-10. PubMed ID: 10838496
[TBL] [Abstract][Full Text] [Related]
18. Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.
Beltrami CM; Dos Reis MB; Barros-Filho MC; Marchi FA; Kuasne H; Pinto CAL; Ambatipudi S; Herceg Z; Kowalski LP; Rogatto SR
Clin Epigenetics; 2017; 9():45. PubMed ID: 28469731
[TBL] [Abstract][Full Text] [Related]
19. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer.
Lin CI; Du J; Shen WT; Whang EE; Donner DB; Griff N; He F; Moore FD; Clark OH; Ruan DT
J Clin Endocrinol Metab; 2011 Mar; 96(3):E554-65. PubMed ID: 21190978
[TBL] [Abstract][Full Text] [Related]
20. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
